"This exceeds my expectations of the knowledge about osteoporosis I could get today. This is amazing"
Live attendee | General Medicine
"Excellent webinar! One of the best webinars I've attended this year."
Live attendee | General Practice
"As a pharmacist I get question[s] from female patients about their bone health and/or their antiresorptive therapies so am better informed to help them"
Live attendee | Community Pharmacy
Related CPD Shorts
Quick, highly focused accredited CPD activities on osteoporosis you can finish in 30 minutes or less. Each comprises a quick video, accompanied by a short Reviewing Performance questionnaire. Earn CPD without blocking out your day. CPD lodged with RACGP automatically within 24 hours.
%20ther.webp)
%20and%20Osteoporosis.webp)
Fracture risk perception and medication adherence
11 mins
In Australia, more than 50% of patients stop taking their osteoporosis medication within 1 to 2 years. Patients often do not associate osteoporosis with fracture risk. Gain practical tips to help them make this connection and encourage them to start/stay on anti-resorptive drugs (ARDs).
.webp)
About this education
A fragility fracture can dramatically change a patient's quality of life¹ - yet osteoporosis remains one of the most underdiagnosed and undertreated conditions in general practice.² With management options having evolved substantially,³ now is the time to update your approach.
In this webinar, Professor Peter Ebeling distills the latest Osteoporosis Position Statement⁴ into a practical, risk-based prescribing framework - covering treatment initiation, specialist referral indications, long-term continuation, the appropriateness of pausing treatment, and strategies for communicating fracture risk to patients.
The second half of the webinar is dedicated entirely to Q&A, giving you direct insights from one of Australia's leading osteoporosis experts in response to real questions asked during the live event.
Learning Outcomes
Upon completion of this education you will be able to:
1
Determine which patients meet criteria for an osteoporosis diagnosis and require pharmacological treatment.
2
Describe the risk-based approach to osteoporosis treatments as outlined in the RACGP Osteoporosis Guidelines and Healthy Bones Australia Position Statement.
3
Compare the risks associated with continuing osteoporosis treatment versus stopping treatment.
4
Communicate to patients the connection between osteoporosis and fracture, and describe the benefits and risks of treatment.
Steering committee
Continuing Professional Development (CPD) Details
This medical education activity has been approved for 1.5 Educational Activity hours and 1 Reviewing Performance hour with:
Activity ID: 1621141
Activity ID: 2407
Activity ID: 42011
Automatic hours lodgement
RACGP and AMA/CPDHome members can now enjoy the convenience of rapid, automatic EA hours lodgement for this education. See your completed hours lodged within 24 hours.*
* Requires correct membership details.
Update yours now >
Please note that any additional reading or learning connected to this activity can be self recorded with your CPD body.
Praxhub is an accredited Major Provider under the RACGP CPD Program.
Praxhub is a Certified Learning Provider under the AMA's CPDHome CPD Program.
Osteoporosis Measuring Outcomes (MO) Mini-Audit
Extend your osteoporosis learning for even greater clinical impact with our measuring outcomes (MO) mini-audit activity - available via any of the activities included in the Strengthening Osteoporosis Care CPD Collection.
Accredited for 5 hours MO.
Praxhub acknowledges Arrotex for its support of this education. The sponsor has provided no input into the content of this activity.
References:
-
Cooper C. Am J Med 1997;103:12S-17S
-
Naik-Panvelkar P, et al. BMC Fam Pract 2020;21(1):32
-
Subarajan P, et al. Endocrinol Metab Clin North Am 2024 ;53:497-512
-
Healthy Bones Australia. Position Statement on the Management of Osteoporosis, November 2025. [Accessed 12 May 2026]